MYCODE® Results reported

Geisinger

6,233 patient-participants have received results* from the Genomic Screening and Counseling Program

For the latest results, see **geisinger.org/MyCode-results.**

October 1, 2025

350,000+ participants have made the success of MyCode possible

550,000 participants nav		ilade tile sace	Coo	of My Cot	10 1	JUSSIDIC
Risk Condition		Patients per condition	8	Gene		Patients per gene
KISK CONDITION						ratients per gene
See						
T						
C	arc	liovascular risk				
Familial hypercholesterolemia§		702	8	APOB		283
(early heart attacks and strokes)		793		LDLR		510
Hereditary transthyretin amyloidosis			夂		Ŕ	
(buildup of amyloid in the body, can lead to heart and		261		TTR		261
nervous system disease)	B		A		B	
Heritable thoracic aortic disease (genetic predisposition to weakening of the wall of the aorta,	8	59	ă	ACTA2	A	59
leading to swelling and sometimes rupture))		7101712		37
Inherited arrhythmias		440		KCNH2		47
(irregular heartbeat with risk for cardiac arrest)		443	累	KCNQ1		244
				SCN5A		152
	ě			BAG3	ă	2
				DSC2		46
				DSG2		79
				DSP		98
				FLNC		57
				LMNA		26
Inherited cardiomyopathies		4.070	A	MYBPC3		234
(diseases of the heart muscle with dangerous complications)		1,262		MYH7		100
			ě	MYL2		10
				MYL3 PKP2		8
				PRKAG2		91 3
	ĕ					1
				RBM20 TNNI3		35
				TNNT2		10
				TPM1		
						6
				TTN		456
						(continued on next page)

MyCode® results reported (continued)

6,233 patient-participants have received results* from the Genomic Screening and Counseling Program

Risk Condition	Patients per condition		Gene		Patients per gene
	Cancer risk			A	
Familial adenomatous polyposis (intestinal polyps and early colon cancer)	66	8	APC		66
Hereditary breast and ovarian cancer§ (early breast, ovarian, prostate, pancreatic and other cancers)	1106		BRCA1 BRCA2		399 707
Hereditary pheochromocytomas and paragangliomas (tumors that can release extra hormones and, rarely, become cancer)	128		SDHAF2 SDHB SDHC SDHD TMEM127		11 55 22 11 29
Li-Fraumeni syndrome (early breast, soft tissue, brain, adrenal and other cancers)	30	A	TP53	ě	30
Lynch syndrome§ (early colon, uterine and other cancers)	653		MLH1 MSH2 MSH6 PMS2		56 38 283 276
Multiple endocrine neoplasia type 1 (tumors that can release extra hormones and, rarely, become cancer)	19		MEN1	ğ	19
Multiple endocrine neoplasia type 2 (early thyroid cancer)	141	A	RET	ă	141
MUTYH-associated polyposis (intestinal polyps and early colon cancer)	7		MUTYH	ð	7
Neurofibromatosis, type 2 (noncancerous tumors in nervous system)	1	P	NF2		1
PALB2-related cancer risk (early onset breast, pancreatic, and ovarian cancers)	167		PALB2		167
Peutz-Jeghers syndrome (early breast, colon, pancreatic and other cancers)	2		STK11		2
Retinoblastoma (early eye cancer)	7		RB1		7
					(continued on next page)

$MyCode @ \ results \ reported \ {\it (continued)}$

6,233 patient-participants have received results* from the Genomic Screening and Counseling Program

Risk Condition		Patients per condition		Gene	Patients per gene
	Can	cer risk (continued)			
Von Hippel-Lindau syndrome (early kidney cancer and benign tumors of the brain, eye, pancreas and adrenal gland)		4		VHL	4
Wilms tumor (malignant kidney tumor)		3	ě	WT1	3
Misc	ella	neous phenotyp	oe:	5	
Biotinindase deficiency (buildup of a B vitamin in the body, can cause issues with the nervous system)		3		BTD	3
Fabry disease (enzyme defect leading to damage of blood vessels in the skin and cells in the kidneys, heart, and nervous system)		10		GLA	10
Hereditary hemochromatosis (too much iron in blood, can lead to liver and heart problems)		648		HFE	648
Hereditary hemorrhagic telangiectasia (abnormal blood vessel formation in skin, mucous membranes, lungs, liver and brain)		53		ACVRL1 ENG	14 39
Juvenile polyposis (intestinal polyps, cancer of the intestine, including colon)		5		BMPR1A	5
Juvenile polyposis / hereditary hemorrhagic telangiecstasia (intestinal polyps, cancer of the intestine, including colon/abnormal blood vessel formation in skin, mucous membranes, lungs, liver & brain)		5		SMAD4	5
Loeys-Dietz syndrome (weakening of the wall of the aorta, leading to swelling and sometimes rupture)		11		SMAD3 TGFBR1 TGFBR2	6 2 3
Malignant hyperthermia (life-threatening condition usually triggered by exposure to certain drugs used for general anesthesia)		279		RYR1	279
Marfan syndrome (connective tissue disease that can cause heart, eye, and skeletal problems)		31	A	FBN1	31
(life-threatening condition usually triggered by exposure to certain drugs used for general anesthesia) Marfan syndrome (connective tissue disease that can cause heart, eye, and					

MyCode® results reported (continued)

6,233 patient-participants have received results* from the Genomic Screening and Counseling Program

Risk Condition		Patients per condition		Gene	Patients per gene
Miscella	nec	ous phenotypes	(con	tinued)	
Maturity-onset diabetes of the young (MODY) (Diabetes in the teens or early adulthood)		15		HNF1A	15
Ornithine transcarbamylase deficiency (buildup of ammonia in the blood, can cause altered mental status and seizures)		4		ОТС	4
Pompe disease (buildup of glycogen which could cause muscle probelms throughout the body)		14		GAA	14
PTEN hamartoma tumor syndrome (early breast, thyroid, uterine and other cancers, with intellectual disability in some cases)		24		PTEN	24
Retinopathy (gradual vision loss, can lead to blindness)		1		RPE65	1
Tuberous sclerosis (multiple types of benign tumors)		30		TSC1 TSC2	8 22
Vascular Ehlers-Danlos syndrome (disease of the connective tissues, including arteries and muscles, that can increase the risk for health complications, such as rupture of arteries)		15		COL3A1	15
Wilson disease (too much copper in the body, can cause liver disease and nervous system issues)		13		АТР7В	13

6,321

§CDC Tier 1 Condition

Totals^{†,‡}



^{*}Number of patient-participants with reported results and the number per gene variant/condition may not be equal due to the possibility of a participant having more than one result.

 $^{^{\}dagger}$ Includes some patients (\sim 12%) already aware of their genomic result from clinical genetic testing. The process of clinical confirmation and disclosure may be modified for these patients

[†]The gene list designated for return has shifted over time (PMID: 33576083). Totals include fewer than 10 results in genes no longer on the return list.